ArticleInfection2026
Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the budget impact on the China's basic medical insurance fund (BMIF) following the inclusion of aztreonam-avibactam (ATM-AVI) for metallo-β-lactamase carbapenem-resistant enterobacterales (MBL-CRE) infections in the National Reimbursement Drug List (NRDL).
methodsA budget impact model was developed with a 2-year time horizon (2026-2027) from the perspective of China's basic medical insurance. The analysis included drug acquisition costs and other direct medical costs. Relevant data were collected from published literature, and supplemented through expert consultation. The study compared costs under two scenarios with and without ATM-AVI reimbursement to estimate its impact on BMIF. One way sensitivity analyses were conducted to identify key parameters influencing the results.
resultsAfter the inclusion of ATM-AVI in the NRDL, the BMIF was projected to save 152,156,598 Chinese yuan (21,310,448 United States dollar) and 210,914,875 Chinese yuan (29,539,898 United States dollar) in 2026 and 2027, respectively. Following reimbursement, ATM-AVI was expected to yield 291 and 342 additional cured patients, 804 and 888 fewer deaths, 11,256 and 13,031 fewer intensive care unit days, and 11,336 and 13,071 fewer total hospitalization days in 2026 and 2027, respectively. Across all parameter variations, ATM-AVI remained cost-saving to BMIF.
conclusionIn China, timely reimbursement of innovative antibiotics can simultaneously improve patient outcomes and reduce medical insurance fund expenditure, underscoring the value of value-based reimbursement policies in promoting access to effective therapies while supporting the sustainability of the health insurance system.
Indexed as
Identifiers
42081046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.